世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000037500

インドの前臨床CRO市場:規模、シェア、動向分析レポート、およびセグメント予測2024-2030

Grand View Research Inc.

India Preclinical CRO Market Size, Share & Trends Analysis Report, And Segment Forecasts, 2024 - 2030

発刊日 2024/02

言語英語

体裁PDF/80ページ

ライセンス/価格80ページ

0000037500

Individual
Team
Enterprise

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

インドの前臨床CROの市場規模、シェア、動向分析レポート:サービス別 (毒性試験)、モデルタイプ別、最終用途別 (バイオ医薬品企業、政府&学術機関)、およびセグメント予測、2024〜2030

市場規模と動向

インドの前臨床CROの市場規模は、2023年に1億8,330万ドルと推定され、2024年から2030年にかけて11.4%のCAGRで成長すると予測されます。市場の成長要因としては、世界的な臨床試験におけるアウトソーシングの傾向と研究開発の増加、技術の進歩の高まり、重要な患者基盤の存在、多数の病院、およびアクセス可能で熟練した人材による低い運営費などがあります。WHOによると、2022年にインドで実施された臨床試験は9,954件でした。

レポート詳細

目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Service
1.2.2. Model type
1.2.3. End use
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Volume price analysis (Model 2)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Service outlook
2.2.2. Model type outlook
2.2.3. Application outlook
2.3. Competitive Insights

Chapter 3. India Preclinical CRO Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. India Preclinical CRO Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Legal landscape
3.3.2.6. Environmental landscape

Chapter 4. India Preclinical CRO Market: Service Estimates & Trend Analysis
4.1. Service Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. India Preclinical CRO Market by Service Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 For The Following
4.4.1. Service
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1.1. Bioanalysis and DMPK studies
4.4.1.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1.1.1.1. In vitro ADME
4.4.1.1.1.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1.1.1.2. In-vivo PK
4.4.1.1.1.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1.2. Toxicology testing
4.4.1.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1.2.1.1. GLP
4.4.1.1.2.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1.2.1.2. Non-GLP
4.4.1.1.2.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1.3. Compound management
4.4.1.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1.3.1.1. Process R&D
4.4.1.1.3.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1.3.1.2. Custom synthesis
4.4.1.1.3.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1.3.1.3. Others
4.4.1.1.3.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1.4. Chemistry
4.4.1.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1.4.1.1. Medicinal chemistry
4.4.1.1.4.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1.4.1.2. Computation chemistry
4.4.1.1.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1.5. Safety pharmacology
4.4.1.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1.6. Others
4.4.1.1.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Model type
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.1.1. Patient Derived Organoid (PDO) model
4.4.2.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.1.2. Patient derived xenograft model
4.4.2.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. End use
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3.1.1. Biopharmaceutical companies
4.4.3.1.2. Government and academic institutes
4.4.3.1.3. Medical device companies

Chapter 5. India Preclinical CRO Market: Model Type Estimates & Trend Analysis
5.1. Model Type Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. India Preclinical CRO Market by Model Type Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 For The Following
5.4.1. Patient Derived Organoid (PDO) model
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Patient derived xenograft model
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. India Preclinical CRO Market: End Use Estimates & Trend Analysis
6.1. End use Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. India Preclinical CRO Market by End Use Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 For The Following
6.4.1. Biopharmaceutical companies
6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Government and academic institutes
6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. Medical device companies
6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.2. Key customers
7.3.3. Key company heat map analysis, 2023
7.4. Company Profiles
7.4.1. Syngene International Limited
7.4.1.1. Company overview
7.4.1.2. Financial performance
7.4.1.3. Product benchmarking
7.4.1.4. Strategic initiatives
7.4.2. Dabur Research
7.4.2.1. Company overview
7.4.2.2. Financial performance
7.4.2.3. Product benchmarking
7.4.2.4. Strategic initiatives
7.4.3. JSS Medical Research
7.4.3.1. Company overview
7.4.3.2. Financial performance
7.4.3.3. Product benchmarking
7.4.3.4. Strategic initiatives
7.4.4. Jubilant Biosys Ltd.
7.4.4.1. Company overview
7.4.4.2. Financial performance
7.4.4.3. Product benchmarking
7.4.4.4. Strategic initiatives
7.4.5. Sugen Life Sciences
7.4.5.1. Company overview
7.4.5.2. Financial performance
7.4.5.3. Product benchmarking
7.4.5.4. Strategic initiatives
7.4.6. Eurofins Advinus
7.4.6.1. Company overview
7.4.6.2. Financial performance
7.4.6.3. Product benchmarking
7.4.6.4. Strategic initiatives
7.4.7. GVRP
7.4.7.1. Company overview
7.4.7.2. Financial performance
7.4.7.3. Product benchmarking
7.4.7.4. Strategic initiatives
7.4.8. Veeda Clinical Research Limited
7.4.8.1. Company overview
7.4.8.2. Financial performance
7.4.8.3. Product benchmarking
7.4.8.4. Strategic initiatives
7.4.9. Axis Clinicals
7.4.9.1. Company overview
7.4.9.2. Financial performance
7.4.9.3. Product benchmarking
7.4.9.4. Strategic initiatives
7.4.10. Syneos Health
7.4.10.1. Company overview
7.4.10.2. Financial performance
7.4.10.3. Product benchmarking
7.4.10.4. Strategic initiatives
7.4.11. Ethicare-cro
7.4.11.1. Company overview
7.4.11.2. Financial performance
7.4.11.3. Product benchmarking
7.4.11.4. Strategic initiatives
7.4.12. Liveon Biolabs Pvt.Ltd.
7.4.12.1. Company overview
7.4.12.2. Financial performance
7.4.12.3. Product benchmarking
7.4.12.4. Strategic initiatives
7.4.13. IQVIA Inc
7.4.13.1. Company overview
7.4.13.2. Financial performance
7.4.13.3. Product benchmarking
7.4.13.4. Strategic initiatives
7.4.14. Bioneeds
7.4.14.1. Company overview
7.4.14.2. Financial performance
7.4.14.3. Product benchmarking
7.4.14.4. Strategic initiatives
7.4.15. TheraIndx Lifesciences Pvt. Ltd.
7.4.15.1. Company overview
7.4.15.2. Financial performance
7.4.15.3. Product benchmarking
7.4.15.4. Strategic initiatives

List of Tables
Table 1 List of abbreviations
Table 2 India preclinical CRO market, by service, 2018 - 2030 (USD Million)
Table 3 India preclinical CRO market, by model type, 2018 - 2030 (USD Million)
Table 4 India preclinical CRO market, by end use, 2018 - 2030 (USD Million)

List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Market research approaches
Fig. 4 Value-chain-based sizing & forecasting
Fig. 5 QFD modeling for market share assessment
Fig. 6 Market formulation & validation
Fig. 7 India preclinical CRO market: market outlook
Fig. 8 India preclinical CRO competitive insights
Fig. 9 Parent market outlook
Fig. 10 Related/ancillary market outlook
Fig. 11 Penetration and growth prospect mapping
Fig. 12 Industry value chain analysis
Fig. 13 India preclinical CRO market driver impact
Fig. 14 India preclinical CRO market restraint impact
Fig. 15 India preclinical CRO market strategic initiatives analysis
Fig. 16 India preclinical CRO market: Service movement analysis
Fig. 17 India preclinical CRO market: Service outlook and key takeaways
Fig. 18 Bioanalysis and DMPK studies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 In vitro ADME market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 In-vivo PK market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Toxicology testing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 GLP market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Non-GLP market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Compound management market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Process R&D market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Custom synthesis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Chemistry market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Medicinal chemistry market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Computation chemistry market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Safety pharmacology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 India preclinical CRO market: Model type movement analysis
Fig. 34 India preclinical CRO market: Model type outlook and key takeaways
Fig. 35 Patient Derived Organoid (PDO) model market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Patient derived xenograft model market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 India preclinical CRO market: End use movement analysis
Fig. 38 India preclinical CRO market: End use outlook and key takeaways
Fig. 39 Biopharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Government and academic institutes market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Medical device companies market estimates and forecasts, 2018 - 2030 (USD Million)

この商品のレポートナンバー

0000037500

TOP